MATWIN and Pierre Fabre Fund for Innovation strengthen partnership

Published: 9-May-2016
Research & Development

To boost the development of innovative projects in oncology


Maturation & Accelerating Translation With Industry (MATWIN), a France-based support programme for early innovation in oncology, has strengthened its collaboration with Pierre Fabre Laboratories ahead of this week's MEET2WIN Oncology Business Convention.

Pierre Fabre has been a partner of MATWIN since 2014 and will expand its contribution to this year's convention, which is dedicated to open innovation and collaborative research in oncology, and takes place on 12–13 May in Bordeaux, France. More than 200 participants involved in the oncology innovation cycle are expected to attend.

At the meeting, several research projects in oncology and onco-dermatology pre-selected by MATWIN will be evaluated by the Pierre Fabre Fund for Innovation. If selected and a partnership signed, these projects will benefit from the support and expertise of the Pierre Fabre Group across the spectrum of R&D activities and/or from financial support for their project to advance through the clinic.

'Biotech entrepreneurs in oncology and onco-dermatology can expect a highly collaborative interaction with us in order to advance projects in the most efficient manner across the product development steps,' said Laurent Audoly, Head of R&D Pierre Fabre Pharmaceuticals and Managing Partner of the Pierre Fabre Fund for Innovation.

We want to offer true flexibility to our partners, without forcing them to follow a set pattern

'This collaboration between MATWIN and Pierre Fabre Fund for Innovation falls into Pierre Fabre Pharmaceuticals' R&D strategy to forge partnerships with external parties showing a real potential for delivering highly differentiated medicines to patients.'

'We want to offer true flexibility to our partners, without forcing them to follow a set pattern. We are willing to take risks on projects that are still at a very early stage of the innovation process. The whole purpose of strengthening our ties with MATWIN is to identify projects of interest,' added Vincent Serra, Operating Manager of the Pierre Fabre Fund for Innovation.

Robert Lucia, CEO of MATWIN, said the new partnership offers additional opportunities for project applications to the organisation.

'It will expand the expertise and support we provide at an early stage, allowing the most promising projects to boost the development of their solutions for unmet medical needs,' he said.

MATWIN is based on a public-private partnership between 12 pharmaceutical companies focusing on oncology (Amgen, AstraZeneca, BayerHealthCare, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) and the French Cancéropôles network.

Since June 2015, MATWIN has become a subsidiary of the Unicancer Group, which brings together the 20 French Comprehensive Cancer Centres.

  • Companies:
  • Pierre Fabre
See more

You may also like

Media

Cellectar Biosciences and Pierre Fabre collaborate to develop drug conjugates

Read more
Cellectar Biosciences, an oncology-focused, clinical stage biotechnology company, together with French pharmaceutical company Pierre Fabre, will extend its ongoing collaboration to develop new phospholipid drug conjugates (PDCs)

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
  3. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  4. Photocatalysed flow method accelerates synthesis of potent MC4R antagonist New automated continuous flow synthesis of spirocyclic tetrahydronaphthyridines for drug discovery
  5. BioMarin Pharmaceutical expands Cork targeted therapy manufacturing facility with new lab The Irish facility is responsible for the development and commercialisation of therapies that address genetic conditions, and this expansion will allow the company to enhance its approved medicine production capacity

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Media

Cellectar Biosciences and Pierre Fabre collaborate to develop drug conjugates

Cellectar Biosciences, an oncology-focused, clinical stage biotechnology company, together with French pharmaceutical company Pierre Fabre, will extend its ongoing collaboration to develop new phospholipid drug conjugates (PDCs)
Ingredients

Pierre Fabre signs partnership with SETUBIO as part of the Nature Open Library programme

SETUBIO will explore the plant collection made available by Pierre Fabre to develop new actives for human and animal health
Research & Development

Pierre Fabre and H-Immune launch research partnership to cancer immunotherapies

Focus on solid tumours provides range of possible cancer indications as targets for immuno-oncology therapeutics
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Optimising scale-up with flow process technologies

Speed of synthesis is of the essence when medicinal chemists invent new molecules, reports Sarah Houlton
Research & Development

Evotec and Pierre Fabre sign five-year compound management agreement

Evotec will handle Pierre Fabre's collection out of its compound management facility in Toulouse
Ingredients

Pierre Fabre and VibioSphen agree new Nature Open Library partnership

Collaboration aims to develop naturally derived compounds to combat antibiotic resistant bacteria
Research & Development

French pharma firm sets up Pierre Fabre Fund for Innovation

To invest in French and European innovators in oncology and dermatology
Subscribe now